MSB 8.42% $1.03 mesoblast limited

Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-124

  1. 225 Posts.
    lightbulb Created with Sketch. 41
    But you did say that this wouldn't change anything in the medium term. That seems to imply that you think this news is insignificant/unimportant.

    This could be the catalyst to partnerships and is potential future money in the coffers. Seems pretty significant/important to me.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.